Form 4: Trevi Therapeutics Director Acquires Stock Options

Michael Heffernan, a Director at Trevi Therapeutics, Inc., acquired 35,000 stock options with an exercise price of $13.45, vesting on June 3, 2026.

Summary

• Michael Heffernan, a Director of Trevi Therapeutics, Inc., was granted 35,000 non-statutory stock options.
• The options have an exercise price of $13.45 per share.
• These options are set to vest on June 3, 2026, or the first anniversary of the grant date, whichever comes first, provided Heffernan continues his service.
• The transaction was reported on June 4, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation event for a director rather than a significant financial or strategic development for the company.

Positives

• Director Michael Heffernan has been granted a significant number of stock options, indicating potential alignment of management interests with shareholder value.
• The grant of options suggests confidence in the company's future prospects by management.

Risks

• The value of the stock options is contingent on the future performance of Trevi Therapeutics' stock price.
• Vesting is subject to continued service, meaning the options could be forfeited if Heffernan leaves the company before the vesting date.

Future Outlook

The vesting schedule for the stock options suggests a forward-looking perspective on the company's performance and the director's continued involvement.

Industry Context

StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, aiming to incentivize long-term performance and align executive interests with those of shareholders, especially for companies like Trevi Therapeutics that are often in development stages.

Stakeholder Impact

• Shareholders: The stock options align director incentives with potential future stock price appreciation, which can benefit shareholders if the company performs well.
• Employees: While not directly impacting employees, such grants can be part of a broader compensation strategy that influences overall company morale and retention.
• Management: The grant reinforces the director's commitment and provides a financial incentive tied to the company's success.

Next Steps

• Michael Heffernan will continue his service as a director to meet vesting requirements for the stock options.
• The stock options will vest on June 3, 2026, or the first anniversary of the grant date, subject to continued service.

Key Dates

Keywords

Trevi Therapeutics, TRVI, Form 4, Stock Options, Director Compensation, Beneficial Ownership, SEC Filing